IDYA Stock Price, Ideaya Biosciences Inc Quote, Chart

Market Summary

USD39.94+1.32

Market Closed

3.42%

IDYA Stock Price

View Fullscreen

IDYA RSI Chart

IDYA Valuation

Market Cap

2.9B

Price/Earnings (Trailing)

-25.49

Price/Sales (Trailing)

123.14

Price/Free Cashflow

-24.49

IDYA Price/Sales (Trailing)

IDYA Profitability

Return on Equity

-18.19%

Return on Assets

-17.4%

Free Cashflow Yield

-4.08%

IDYA Fundamentals

IDYA Revenue

Revenue (TTM)

23.4M

Rev. Growth (Yr)

-2.47%

Rev. Growth (Qtr)

-51.2%

IDYA Earnings

Earnings (TTM)

-113.0M

Earnings Growth (Yr)

-40.3%

Earnings Growth (Qtr)

-23.74%

Breaking Down IDYA Revenue

52 Week Range

18.1140.31

(Low)(High)

Last 7 days

2.6%

Last 30 days

-9.2%

Last 90 days

-8.5%

Trailing 12 Months

109.6%

How does IDYA drawdown profile look like?

IDYA Financial Health

Current Ratio

19.65

IDYA Investor Care

Shares Dilution (1Y)

54.09%

Diluted EPS (TTM)

-1.97

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	47.5M	45.1M	23.5M	23.4M
2022	32.1M	29.1M	49.9M	50.9M
2021	21.6M	23.7M	25.8M	27.9M
2020	0	0	0	19.5M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Ideaya Biosciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 09, 2024	ruiz briseno andres	sold	-92,044	46.0223	-2,000	see remarks
Feb 09, 2024	hata yujiro s	acquired	101,531	4.31	23,557	president and ceo
Feb 09, 2024	hata yujiro s	sold	-1,072,720	45.537	-23,557	president and ceo
Feb 08, 2024	hata yujiro s	acquired	326,763	4.31	75,815	president and ceo
Feb 08, 2024	hata yujiro s	sold	-3,422,840	45.1472	-75,815	president and ceo
Feb 01, 2024	hata yujiro s	sold	-28,260	45.0001	-628	president and ceo
Feb 01, 2024	hata yujiro s	acquired	2,706	4.31	628	president and ceo
Jan 22, 2024	ruiz briseno andres	sold	-84,050	42.0251	-2,000	see remarks
Jan 16, 2024	hata yujiro s	acquired	270,405	4.31	62,739	president and ceo
Jan 16, 2024	hata yujiro s	sold	-2,519,970	40.1659	-62,739	president and ceo

Which funds bought or sold IDYA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 24, 2024	DekaBank Deutsche Girozentrale	unchanged	-	372,000	2,128,000	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-69.55	-163,000	97,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	added	10.44	352,679	1,125,470	0.01%
Apr 19, 2024	JTC Employer Solutions Trustee Ltd	new	-	67,000	67,000	-%
Apr 18, 2024	Park Place Capital Corp	new	-	1,097	1,097	-%
Apr 15, 2024	Legato Capital Management LLC	added	18.46	204,931	649,468	0.08%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	added	32.33	108,080	279,077	0.01%
Apr 11, 2024	Fortitude Family Office, LLC	unchanged	-	41.00	219	-%
Apr 09, 2024	MASSMUTUAL TRUST CO FSB/ADV	new	-	219	219	-%
Apr 09, 2024	Halpern Financial, Inc.	unchanged	-	17,888	94,838	0.03%

Are Funds Buying or Selling IDYA?

Are funds buying IDYA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own IDYA

No. of Funds

Unveiling Ideaya Biosciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	price t rowe associates inc /md/	5.5%	3,568,938	SC 13G
Feb 14, 2024	biotechnology value fund l p	2.8%	1,804,865	SC 13G/A
Feb 14, 2024	avidity partners management lp	2.4%	1,520,000	SC 13G/A
Feb 14, 2024	janus henderson group plc	5.5%	3,551,891	SC 13G
Feb 13, 2024	logos global management lp	2.8%	1,800,000	SC 13G/A
Feb 13, 2024	vanguard group inc	5.39%	3,475,772	SC 13G
Feb 12, 2024	fmr llc	-	0	SC 13G
Feb 07, 2024	adage capital partners gp, l.l.c.	4.54%	2,925,094	SC 13G/A
Feb 01, 2024	canaan x l.p.	2.4%	1,570,820	SC 13G/A
Jan 25, 2024	blackrock inc.	8.4%	5,436,668	SC 13G/A

Recent SEC filings of Ideaya Biosciences Inc

View All Filings

Date Filed	Form Type	Document
Apr 24, 2024	ARS	ARS
Apr 19, 2024	DEF 14A	DEF 14A
Mar 12, 2024	8-K	Current Report
Mar 04, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading
Feb 20, 2024	10-K	Annual Report
Feb 20, 2024	8-K	Current Report

Peers (Alternatives to Ideaya Biosciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	40.6B	6.8B	-1.15%	-18.78%	-8.61	5.92	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.46%	-27.26%	-41.1	9.9	76.23%	61.08%
BMRN	15.5B	2.4B	-6.36%	-11.66%	92.47	6.41	15.42%	18.43%
INCY	11.5B	3.7B	-9.50%	-30.40%	19.23	3.11	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.85%	-43.46%	-10.93	14.57	425.83%	18.94%
BBIO	4.3B	-	-18.25%	70.26%	-6.55	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-6.76%	2.03%	-14.16	12.52	440.80%	-27.84%
ARWR	2.7B	240.7M	-21.52%	-38.49%	-9.13	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-8.32%	-19.69%	-43.85	3.7	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.79%	-8.36%	24.23	4.35	85.90%	-14.05%
NVAX	552.8M	983.7M	-16.14%	-47.54%	-1.01	0.56	-50.36%	17.16%
CRBP	351.2M	881.7K	-7.41%	335.24%	-7.87	466.16	-77.61%	-5.33%
INO	236.5M	4.9M	-18.26%	4.12%	-1.75	48.6	-54.97%	51.71%
IBIO	5.9M	2.1M	47.83%	55.96%	-0.22	2.14	-13.45%	66.37%

Ideaya Biosciences Inc News

Latest updates

Ideaya Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)														(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Revenue	-51.2%	3,923	8,038	3,544	7,880	4,022	29,699	5,851	11,359	2,962	8,976	8,756	7,247	8,107	8,967
Operating Expenses	10.3%	45,839	41,564	36,253	34,159	30,465	29,039	28,350	25,579	21,331	20,689	19,807	16,382	15,851	13,963
S&GA Expenses	-10.1%	7,069	7,863	7,075	6,300	5,753	6,667	5,554	5,923	5,221	5,186	4,828	4,816	3,800	3,938
R&D Expenses	15.0%	38,770	33,701	29,178	27,859	24,713	22,372	22,796	19,656	16,110	15,503	14,979	11,566	12,051	10,025
Interest Expenses	190.9%	32.00	11.00	13.00	13.00	14.00	14.00	16.00	16.00	16.00	18.00	18.00	19.00	20.00	20.00
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-23.7%	-33,955	-27,440	-27,926	-23,640	-24,201	1,615	-22,056	-14,013	-18,212	-11,582	-10,947	-9,021	-5,135	-4,926
Net Income Margin	-9.9%	-4.83*	-4.39*	-1.64*	-1.44*	-1.15*	-1.06*	-2.26*	-1.71*	-1.78*	-1.42*	-1.26*	-1.45*	-1.77*	-
Free Cashflow	20.1%	-24,586	-30,777	-34,344	-27,885	-23,370	-25,267	-21,933	-20,048	-17,262	-12,926	-13,508	-14,727	-11,775	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																				(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Assets	21.8%	649	533	528	365	388	411	338	359	381	399	328	326	298	301	185	102	113	122	133	97.00
Current Assets	10.5%	533	482	502	344	370	393	272	256	251	269	280	308	289	281	174	89.00	102	112	123	91.00
Cash Equivalents	3.4%	157	152	103	67.00	69.00	102	49.00	55.00	92.00	108	90.00	137	72.00	81.00	148	35.00	34.00	39.00	88.00	21.00
Net PPE	-0.5%	6.00	6.00	7.00	7.00	7.00	7.00	7.00	5.00	5.00	5.00	5.00	5.00	4.00	4.00	4.00	4.00	5.00	5.00	5.00	5.00
Liabilities	13.4%	28.00	25.00	26.00	31.00	39.00	42.00	69.00	70.00	80.00	82.00	88.00	93.00	100	106	12.00	13.00	13.00	12.00	13.00	7.00
Current Liabilities	8.9%	27.00	25.00	25.00	30.00	32.00	33.00	58.00	57.00	45.00	39.00	36.00	36.00	39.00	54.00	7.00	7.00	7.00	6.00	6.00	5.00
Shareholder's Equity	22.3%	621	508	502	334	349	369	269	289	302	318	240	233	198	195	172	89.00	100	110	121	-
Retained Earnings	-10.8%	-348	-314	-287	-259	-235	-211	-212	-190	-176	-158	-147	-136	-126	-121	-116	-104	-92.49	-81.71	-70.74	-50.52
Additional Paid-In Capital	17.7%	969	823	790	594	588	584	486	482	479	476	387	369	325	317	289	194	193	192	191	2.00
Shares Outstanding	10.9%	65.00	59.00	57.00	48.00	48.00	39.00	39.00	39.00	35.00	38.00	33.00	32.00	-	-	-	-	-	-	-	-
Float	-	-	-	1,300	-	-	-	493	-	-	-	629	-	-	-	343	-	-	-	135	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	21.3%	-23,748	-30,174	-33,460	-27,842	-23,370	-24,166	-19,992	-19,647	-16,657	-12,468	-12,930	-13,724	-11,596	90,210	-13,606	-9,545	-8,706	-10,550	-10,272	-9,785	-7,477
Share Based Compensation	-9.5%	4,798	5,301	4,731	3,659	2,975	3,005	3,044	2,605	2,064	2,197	2,058	1,918	1,046	981	824	758	719	518	548	383	325
Cashflow From Investing	-318.0%	-111,943	51,347	-121,381	23,521	-10,276	-18,683	13,316	-17,761	-413	-56,307	-49,381	36,435	-4,554	-183,583	30,988	10,906	3,887	-38,441	11,411	25,408	6,576
Cashflow From Financing	406.2%	140,894	27,834	191,063	2,926	324	95,697	491	653	688	86,776	15,986	42,004	6,949	27,068	94,699	34.00	38.00	-276	51,674	-826	-77.00
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2.00	2.00	-	-	-

IDYA Income Statement

2023-12-31

Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Collaboration revenue	$ 23,385	$ 50,931	$ 27,941
Operating expenses
Research and development	129,508	89,536	58,158
General and administrative	28,306	23,897	20,051
Total operating expenses	157,814	113,433	78,209
Loss from operations	(134,429)	(62,502)	(50,268)
Interest income and other income (expense), net	21,468	3,847	506
Net loss	(112,961)	(58,655)	(49,762)
Unrealized gains (losses) on marketable securities	3,433	(2,159)	(719)
Comprehensive loss	$ (109,528)	$ (60,814)	$ (50,481)
Net loss per common share, basic	$ (1.96)	$ (1.42)	$ (1.41)
Net loss per common share, diluted	$ (1.96)	$ (1.42)	$ (1.41)
Weighted-average number of common shares outstanding used in computing net loss per share, basic	57,519,929	41,444,696	35,252,443
Weighted-average number of common shares outstanding used in computing net loss per share, diluted	57,519,929	41,444,696	35,252,443

IDYA Balance Sheet

2023-12-31

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 157,018	$ 68,632
Short-term marketable securities	368,096	296,197
Accounts receivable	18	211
Prepaid expenses and other current assets	7,500	5,414
Total current assets	532,632	370,454
Restricted cash	757	106
Long-term marketable securities	107,492	8,317
Property and equipment, net	6,164	6,509
Right-of-use asset	2,246	2,484
Other non-current assets	25	99
Total assets	649,316	387,969
Current liabilities
Accounts payable	6,598	4,280
Accrued liabilities	18,756	16,999
Contract liability		8,568
Operating lease liabilities, current	1,747	1,871
Total current liabilities	27,101	31,718
Long-term contract liability		5,185
Long-term operating lease liabilities	1,125	1,611
Total liabilities	28,226	38,514
Commitments and contingencies (Note 6)
Stockholders’ equity
Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of December 31, 2023 and December 31, 2022; no shares issued and outstanding as of December 31, 2023 and December 31, 2022
Common stock, $0.0001 par value, 300,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 65,039,369 and 48,193,179 shares issued and outstanding as of December 31, 2023 and December 31, 2022	7	5
Additional paid-in capital	968,885	587,724
Accumulated other comprehensive income (loss)	562	(2,871)
Accumulated deficit	(348,364)	(235,403)
Total stockholders’ equity	621,090	349,455
Total liabilities and stockholders’ equity	$ 649,316	$ 387,969

About Ideaya Biosciences Inc

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase II clinical trial for patients with solid tumors having methylthioadenosine phosphorylase gene deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester todevelop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase II/III study in metastatic uveal melanoma, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

CEO	Mr. Yujiro S. Hata
WEBSITE	ideayabio.com
INDUSTRY	Biotechnology
EMPLOYEES	116

Ideaya Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Ideaya Biosciences Inc? What does IDYA stand for in stocks?

IDYA is the stock ticker symbol of Ideaya Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ideaya Biosciences Inc (IDYA)?

As of Thu Apr 25 2024, market cap of Ideaya Biosciences Inc is 2.88 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IDYA stock?

You can check IDYA's fair value in chart for subscribers.

What is the fair value of IDYA stock?

You can check IDYA's fair value in chart for subscribers. The fair value of Ideaya Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ideaya Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IDYA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ideaya Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether IDYA is over valued or under valued. Whether Ideaya Biosciences Inc is cheap or expensive depends on the assumptions which impact Ideaya Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IDYA.

What is Ideaya Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 25 2024, IDYA's PE ratio (Price to Earnings) is -25.49 and Price to Sales (PS) ratio is 123.14. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IDYA PE ratio will change depending on the future growth rate expectations of investors.